GLPBio

Factor Xa

Read More about this category

Factor Xa is a trypsin-like serine protease that catalyzes the cleavage of peptide bonds on the carboxyl side (P’1) of a basic amino acid residue with a preference to cleave peptide bonds of carboxyl function provided by an argininyl residue. Factor Xa plays an essential role in the coagulation cascade catalyzing the conversion of prothrombin to thrombin on surface of vascular cells to link the extrinsic and intrinsic pathways, in which it forms the Ca2+- and phospholipid-dependent prothrombinase complex with cofactor V/Va on activated platelets, monocytes or endothelial cells. Moreover, factor Xa has been found to mediate the stimulation of lymphocyte proliferation, induce the mitogenesis of endothelial and smooth muscle cells, and trigger acute inflammatory responses in vivo.

Products Related to Factor Xa(59)

  • GC46879 structure
    GC46879Argatroban-d3 (hydrochloride)
    CAS: 1356847-56-7
    Purity: >99.00%

    An internal standard for the quantification of argatroban

  • GC47165 structure
    GC47165Dabigatran etexilate-d13
    CAS: 2749293-92-1
    Purity: >99.00%

    A neuropeptide with diverse biological activities

  • GC47280 structure
    GC47280Edoxaban-d6
    CAS: 1304701-57-2
    Purity: >99.00%

    An internal standard for the quantification of edoxaban

  • GC49118 structure
    GC4911810-hydroxy Warfarin
    CAS: 83219-99-2
    Purity: >95.00%

    A metabolite of (R)-warfarin

  • GC49131 structure
    GC49131Dehydro Warfarin
    CAS: 67588-18-5
    Purity: >95.00%

    A metabolite of (±)-warfarin

  • GC49322 structure
    GC49322GGACK (hydrochloride)
    Purity: >95.00%

    A uPA and factor Xa inhibitor

  • GC49518 structure
    GC49518Fluindione
    CAS: 957-56-2
    Purity: >98.00%

    A vitamin K antagonist

  • GC49614 structure
    GC49614Acenocoumarol-d4
    CAS: 2937878-24-3
    Purity: >99.00%

    Acenocoumarol-d4 is deuterium labeled Acenocoumarol.

  • GC49682 structure
    GC49682Dabigatran-d3
    CAS: 1246817-44-6
    Purity: >99.00%

    An internal standard for the quantification of dabigatran

  • GC49684 structure
    GC49684Dabigatran-13C-d3
    CAS: 2967480-55-1
    Purity: >99.00%

    An internal standard for the quantification of dabigatran

  • GC60326 structure
    GC60326Rivaroxaban D4
    CAS: 1132681-38-9
    Purity: >98%

    An internal standard for the quantification of rivaroxaban

  • GC61748 structure
    GC61748Betrixaban D6
    CAS: 2098655-51-5
    Purity: >98.50%

    Betrixaban D6 is a deuterium labeled Betrixaban.

  • GC62298 structure
    GC62298Edoxaban impurity 4
    CAS: 480452-36-6
    Purity: >98%

    Edoxaban impurity 4 is an impurity of Edoxaban.

  • GC62439 structure
    GC62439Edoxaban impurity 6
    CAS: 480452-37-7
    Purity: >98%
  • GC62922 structure
    GC62922Darexaban
    CAS: 365462-23-3
    Purity: >99.50%

    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM.

  • GC63873 structure
    GC63873Milvexian
    CAS: 1802425-99-5
    Purity: >98%

    Milvexian (BMS-986177), an effective antithrombotic agent, is an orally-bioavailable, reversible and direct inhibitor of human and rabbit factor XIa (FXIa) with Ki of 0.11, and 0.38 nM, respectively.

  • GC65060 structure
    GC65060Fitusiran
    CAS: 1499251-18-1
    Purity: >94.50%

    Fitusiran is a kind of small interfering RNA (siRNA) therapeutic for hemophilia.

  • GC65912 structure
    GC65912Asundexian
    CAS: 2064121-65-7
    Purity: >99.50%

    Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM.

  • GC68034 structure
    GC68034Enoxaparin
    CAS: 679809-58-6
    Purity: >98%
  • GC68593 structure
    GC68593Abelacimab
    CAS: 2098724-83-3
    Purity: >98%

    Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic domain of FXI and locks it in the zymogen conformation, preventing its activation by either FXIIa or thrombin. Abelacimab can be used for research on thrombotic diseases.

  • GC68778 structure
    GC68778BMS-262084
    CAS: 253174-92-4
    Purity: >98.00%

    BMS-262084 is an effective, selective, and irreversible inhibitor of factor XIa with an IC50 value of 2.8 nM for human factor XIa. BMS-262084 also inhibits human pancreatic trypsin (IC50=5 nM). BMS-262084 has anti-thrombotic properties.

  • GC69151 structure
    GC69151Garadacimab
    CAS: 2162134-62-3
    Purity: >95.00%

    Garadacimab (CSL312) is a first-in-class fully human IgG4 monoclonal antibody that targets activated factor XII (FXIIa). Garadacimab has the potential for use in research on hereditary angioedema.

  • GC70535 structure
    GC70535Zifaxaban
    CAS: 1378266-98-8

    Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa.

  • GC70672 structure
    GC70672Fitusiran sodium
    Purity: >94.00%

    Fitusiran sodium, an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver.